Top Markets
#1 ORDI ORDI +75.07%
#2 tomiNet tomiNet +42.74%
#3 1000SATS (Ordinals) 1000SATS (Ordinals) +37.39%
#4 SATS (Ordinals) SATS (Ordinals) +36.77%
#5 pippin pippin +33.93%
#6 Axelar Axelar +33.55%
#7 Swarms Swarms +25.58%
#8 Bio Protocol Bio Protocol +23.17%
#9 Walrus Walrus +20.25%
#10 Zerebro Zerebro +20.22%
Coin of the day
ORDI ORDI
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rang in Aktien #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aktienkurs
$0.00047446
Marktkapitalisierung
$82.80
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Kategorie

Healthcare
Operative Marge für Neovacs S.A. (ALNEV)
Operative Marge zum April 2026 TTM: -1,846.44%
Laut den neuesten Finanzberichten und dem Aktienkurs von Neovacs S.A. beträgt die aktuelle operative Marge (TTM) -1,846.44%. Am Ende des Jahres 2023 lag die operative Marge bei -1,294.97%.
Historie der operativen Marge von Neovacs S.A. von 2007 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
2026 (TTM) -1,846.44% 0.00%
2024 -1,846.44% 42.59%
2023 -1,294.97% -99.78%
2022 -579,583.27% 1,570.47%
2021 -34,695.90% 195.85%
2020 -11,727.38% 0.00%
2019 0.00% -100.00%
2018 -9,020.69% 0.00%
2017 0.00% -100.00%
2016 -111,411.14% 1,245.37%
2015 -8,281.07% 22.13%
2014 -6,780.72% -74.35%
2013 -26,437.94% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% -100.00%
2008 -12,827.49% 212.34%
2007 -4,106.85% 0.00%
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.02%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.02%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.01%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.01%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
25.64% -100.01%
NL
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.